Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01213641 · ClinicalTrials.gov registry record
Clinical Outcomes and Safety: A Registry Study of Ilaris (Canakinumab) Patients
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 288
- Enrollment target
NCT01213641: Completed study, sponsored by Novartis Pharmaceuticals.
NCT01213641 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 288 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01213641 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 288 participants
- Enrollment target
Study Summary
The purpose of this observational study is to collect additional information regarding long-term safety and effectiveness of Ilaris in the treatment of CAPS patients in clinical practice.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 288 participants |
| Start Date | 2009-11 |
| Est. Completion | 2015-12 |
What the finished NCT01213641 record still lists
NCT01213641 is an observational study that tracks outcomes without assigning an intervention. The registered 288 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT01213641 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01213641 about?
NCT01213641 is a clinical study titled "Clinical Outcomes and Safety: A Registry Study of Ilaris (Canakinumab) Patients". The purpose of this observational study is to collect additional information regarding long-term safety and effectiveness of Ilaris in the treatment of CAPS patients in clinical practice.
What is the current status of trial NCT01213641?
This trial is currently completed. The enrollment target is 288 participants. The study started on 2009-11. Estimated completion is 2015-12.
Who is sponsoring clinical trial NCT01213641?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02098265 · 288 participants · NA
A Closed Loop Neural Activity Triggered Stroke Rehabilitation Device
- NCT03741777 · 288 participants · NA
Comparison of Residual Gastric Volume Between Children Who Drink Different Clear Oral Fluid Volume
- NCT03937635 · 288 participants · Phase 3
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
- NCT04621877 · 288 participants · NA
Lay-Delivered Behavioral Activation in Senior Centers
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia